While Moderna and Pfizer-BioNTech have submitted Emergency Use Authorization (EUA) requests for their COVID-19 vaccines, the data so far suggest the benefits of a fourth shot may be modest.
The U.S. Food and Drug Administration on December 3 authorized the use of Eli Lilly’s Covid-19 dual-antibody therapy in treating mild to moderate symptoms in all children, including newborns, who are at risk of severe illness.
The U.S. Food and Drug Administration approved AbbVie’s Dalvance (dalbavancin) for acute bacterial skin and skin structure infections in pediatric patients as young as newborns.
In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines, Covid-19 antibodies last at least three months and so do symptoms for many.
Roche said two-thirds of spinal muscular atrophy (SMA) patients taking the Swiss drugmaker’s newly approved medicine Evrysdi have previously received rival treatments Zolgensma from Novartis or Biogen’s Spinraza.
A new wireless system for monitoring the vital signs of the most fragile newborns – those born prematurely or with debilitating diseases – could make it easier for parents to have skin to skin contact with their babies, a preliminary study suggests.
Abbott announced the U.S. Food and Drug Administration approved the Amplatzer Piccolo Occluder, the world’s first medical device that can be implanted in the tiniest babies using a minimally invasive procedure to treat patent ductus arteriosus (PDA).